Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

被引：3
|
作者：
Gumus, Mahmut
Chen, Chieh-I
Ivanescu, Cristina
Kilickap, Saadettin
Bondarenko, Igor
Ozguroglu, Mustafa
Gogishvili, Miranda
Turk, Haci M.
Cicin, Irfan
Harnett, James
Mastey, Vera
Naumann, Ulrike
Reaney, Matthew
Konidaris, Gerasimos
Sasane, Medha
Brady, Keri
Li, Siyu
Gullo, Giuseppe
Rietschel, Petra
Sezer, Ahmet
机构：
[1] Istanbul Medeniyet Univ, Istanbul, Turkey
[2] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[3] IQVIA, Durham, NC USA
[4] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey
[5] Dnipropetrovsk State Med Acad, City Multifield Clin Hosp, Dnepropetrovsk, Ukraine
[6] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Istanbul, Turkey
[7] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia
[8] Bezmialem Vakif Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey
[9] Trakya Univ, Dept Med Oncol, Edirne, Turkey
[10] Sanofi, Reading, Berks, England
[11] Sanofi, Bridgewater, NJ USA
[12] Sanofi, Cambridge, MA USA
[13] Baskent Univ, Dept Med Oncol, Adana, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9078
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater
    Tambo, Yuichi
    Sone, Takashi
    Shibata, Kazuhiko
    Nishi, Kouichi
    Shirasaki, Hiroki
    Yoneda, Taro
    Araya, Tomoyuki
    Kase, Kazumasa
    Nishikawa, Shingo
    Kimura, Hideharu
    Kasahara, Kazuo
    ANNALS OF ONCOLOGY, 2021, 32 : S313 - S313
  • [42] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Li, Yeran
    El-Osta, Hazem
    Pietanza, M. Catherine
    Burke, Thomas
    CANCERS, 2022, 14 (04)
  • [43] Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1-Selected Patients With Advanced NSCLC
    Carcereny, E.
    Felip, E.
    Reck, M.
    Patel, J.
    Heist, R.
    Balmanoukian, A.
    Chow, L.
    Paz-Ares, L.
    Qiu, J.
    Coleman, S.
    Mocci, S.
    Sandler, A.
    Kurata, T.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1791 - S1792
  • [44] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
    Wu, Y.
    Zhang, L.
    Fan, Y.
    Zhou, J.
    Zhang, L.
    Zhou, Q.
    Li, W.
    Hu, C.
    Chen, G.
    Zhang, X.
    Zhou, C.
    Dang, T.
    Penrod, J.
    Kush, D.
    Qin, Y.
    Li, B.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
  • [45] First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial
    Ren, Shengxiang
    Wang, Xicheng
    Han, Bao-Hui
    Pan, Yueyin
    Zhao, Jun
    Cheng, Yufeng
    Hu, Sheng
    Liu, Tianshu
    Li, Yalun
    Cheng, Ying
    Feng, Jifeng
    Yi, Shanyong
    Gu, Shanzhi
    Gao, Shegan
    Luo, Yongzhong
    Liu, Ying
    Liu, Caigang
    Duan, Huijie
    Wang, Shuni
    Yang, Xinfeng
    Fan, Jia
    Zhou, Caicun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (02)
  • [46] Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.
    Kuznik, Andreas
    Smare, Caitlin
    Chen, Chieh-I
    Venkatachalam, Meena
    Keeping, Sam
    Atsou, Kokuvi
    Xu, Yingxin
    Wilson, Florence
    Guyot, Patricia
    Chan, Keith
    Glowienka, Emily
    Konidaris, Gerasimos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis
    Garcia Campelo, Maria Rosario
    Arriola, Edurne
    Campos Balea, Begona
    Lopez-Brea, Marta
    Fuentes-Pradera, Jose
    de Castro Carpeno, Javier
    Aguado, Carlos
    Perez Parente, Diego
    de Oro Pulido, Fidel
    Ruiz-Gracia, Pedro
    Rodriguez-Abreu, Delvys
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (19)
  • [48] PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
    Garcia Campelo, M. R.
    Arriola Aperribay, E.
    Campos Balea, B.
    Lopez-Brea, M.
    Fuentes Pradera, J.
    de Castro Carpeno, J.
    Aguado, C.
    Perez Parente, D.
    de Oro-Pulido, F.
    Rodriguez Abreu, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S1413 - S1414
  • [49] IMPACT OF CRIZOTINIB TREATMENT ON PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) IN ASIAN PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Shi, Yuankai
    Iyer, S.
    Kim, Dong-wan
    Reisman, A.
    Liu, Xiaoquing
    Nakagawa, K.
    Yang, P.
    Ahn, M-J
    Milner, Keith
    Hida, Toyoaki
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S491 - S491
  • [50] Real-World Data (RWD) Of First-Line Cemiplimab Single Agent for Advanced PD-L1 High Expression, Non-Small Cell Lung Cancer (NSCLC)
    Masini, S.
    Garrido, A.
    Alvarez, R.
    Antonanzas, M.
    Navarro, F.
    Traseira, C.
    Cabezon, L.
    Garcia, C.
    Falagan, S.
    Rocha, P.
    Mosquera, J.
    Azkarate, A.
    Garcia-Lorenzo, E.
    Martin-Soberon, M. C.
    Sequero, S.
    Sereno, M.
    Lage, Y.
    Peressini, M.
    Cortijo, S.
    Bote, H.
    Torres-Jimenez, J.
    Zurera, M.
    Paz-Ares, L.
    Zugazagoitia, J.
    Baena, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S405 - S405
12345